Research & Development
Aspira Women’s Health, Dana-Farber Cancer Institute ink agreement to develop ovarian cancer test
The test would use a Dana-Farber microRNA ovarian cancer signature with Aspira’s artificial intelligence/machine learning algorithms to identify ovarian cancer in patients with adnexal masses.
May 11, 2023
Aspira Women’s Health announces milestones for expanded access to ovarian cancer risk test
The 2023 Omnibus Spending Bill contains language directing CMS to cover multimarker tests for ovarian cancer, increasing access to this testing; the expansion could encourage commercial insurers to adopt similar coverage policies.
December 27, 2022
Aspira Women's Health, BioReference to distribute blood tests to detect the risk of ovarian malignancy
The firms will co-market and distribute Aspira's Ova1Plus, which combines its Ova1 and Overa blood tests to detect the risk of ovarian malignancy in women with adnexal masses prior to surgery.
October 5, 2022
Aspira announces results of ovarian cancer assay study
Researchers prospectively compared various diagnostic methods, including ultrasound/IOTA (International Ovarian Tumor Analysis Rules), the biomarker CA-125, and Overa, evaluating them for their ability to detect ovarian cancer. The results were correlated with surgical findings.
September 13, 2022
Gradalis touts ovarian cancer biomarker research
The study includes results from a phase IIB trial of Vigil in patients with newly diagnosed ovarian cancer, and shows that pretreatment levels of a gene called ENTPD1 may help predict overall and recurrence-free ovarian cancer survival after treatment with Vigil. The ENTPD1 gene "is a protein coding gene that functions as a limiting step in the adenosine metabolic pathway found in immunosuppressive tumor microenvironments," Gradalis said, and "high ENTPD1 expression predicts response to Vigil versus placebo regardless of homologous recombination status."
August 28, 2022
Clinics begin adopting Genetic Technologies risk test
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Sophia Genetics and Realm IDx to collaborate
The two firms plan to explore the further development of Realm IDx subsidiary Ambry Genetics' TumorNext-HRD (homologous recombination deficiency) ovarian cancer test as well as the possibility of combining Ambry's Variant Assessment database with Sophia Genetics' Sophia DDM platform for HRD detection.
March 13, 2022
Lunaphore, MGH collaborate on IVD work for solid tumors
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
Illumina, Merck partner on HRD test
Illumina will leverage its TruSight oncology (TSO) 500 content to develop a new HRD CDx test for the European Union and the U.K. to aid in the identification of ovarian cancer patients with positive HRD status who are eligible for treatment with Lynparza, an (ADP-ribose) polymerase inhibitor.
September 7, 2021
FDA clears Foundation's FoundationOne Liquid CDx
The new indications are for alpelisib (Piqray) for advanced or metastatic breast cancer; rucaparib (Rubraca) for advanced ovarian cancer; and alectinib (Alecensa) for metastatic NSCLC.
October 28, 2020
Medicare to pay for Myriad's BRCA testing in prostate cancer patients
Lynparza is approved for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. BRCA testing in prostate cancer has been gaining steam with the approval of new indications for Lynparza (Merck/AstraZeneca) and other PARP inhibitors for this tumor type, building on the original approved use for treatment of ovarian cancer.
July 30, 2020
Page 1 of 3